Navigation Links
EntreMed Reports First Quarter 2011 Financial Results
Date:5/16/2011

ROCKVILLE, Md., May 16, 2011 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today announced financial results for the three months ended March 31, 2011.  

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

The Company reported a net loss for the first quarter of approximately ($2.6 million), or ($0.25) per share, compared with a net loss of ($2.1 million), or ($0.28) per share, for the same period last year.  The Company did not report any revenues for the first quarter 2011.  As of March 31, 2011, the Company had cash and short-term investments of approximately $4.8 million.  

Sara B. Capitelli, Vice President, Finance and Principal Accounting Officer, commented on the Company's first quarter results, "Our first quarter 2011 financial results were in line with expectations.  R&D expenses for the first quarter increased over the previous year as we continued to enroll patients in the ENMD-2076 Phase 2 ovarian cancer study.  The Company fulfilled its term loan obligation to GE Capital Corporation and the loan was repaid in full on January 3, 2011."

Michael M. Tarnow, Executive Chairman, commented, "During the first quarter, we remained diligent in our strategy for the development of ENMD-2076 while carefully managing our financial resources.  Earlier this year, we were pleased to announce the completion of enrollment for the ENMD-2076 Phase 2 study in patients with platinum resistant ovarian cancer. The trial is progressing and the data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in June."  

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-c
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Reports Third Quarter 2010 Financial Results
2. EntreMed Receives Notice of NASDAQ Compliance
3. EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China
4. EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
5. EntreMed Reports Second Quarter 2010 Financial Results
6. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. EntreMed Presents Initial Clinical Results for ENMD-2076
9. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
10. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  ACI Clinical ( www.aciclinical.com ... Data Monitoring Committees. Using this solution, ... over industry standard costs and receive the same ... in committee services. Leveraging a decade ... contracting, charter development, statistical programming and meeting facilitation), ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  The board ... ), a leading provider of clinical trial imaging solutions, ... been named chief financial officer, effective immediately.  Mr. Groff ... since August 2013.  He joined VirtualScopics in January 2006 ... in February 2013. "When the board of ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... NOVATO, Calif., Aug. 30 BioMarin Pharmaceutical Inc. (Nasdaq: ... received orphan drug designation from the U.S. Food and ... insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in ... new drug application (IND) for BMN-701 has been submitted, ...
... ROCKVILLE, Md., Aug. 30 Sequella, Inc., a ... for life-threatening infectious diseases, announced today the restatement ... University of Maryland, Baltimore (UMB), concerning certain technology ... technology patent (U.S. 6,663,846), jointly owned by Sequella ...
Cached Medicine Technology:BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease 2BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease 3Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 2Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 3
(Date:8/21/2014)... a woman is to focus on her body in ... than viewing her as a complete human being with ... a problem in the media, how does it affect ... of Women Quarterly , a SAGE journal, finds that ... to higher incidents of sexual pressure and coercion., Researchers ...
(Date:8/21/2014)... Researchers in the United Kingdom have demonstrated that advanced ... diagnose a number of rare diseases marked by childhood ... today in Ophthalmology , the journal of the ... doctors were able to tailor care specifically to a ... and money spent on diagnosis and enabling earlier treatment ...
(Date:8/21/2014)... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) filings ... uncontrollable internal bleeding and other serious injuries continue to ... to court documents, a wrongful death lawsuit was filed ... of New York by the family of a Tennessee ... was allegedly caused by Xarelto. Among other thing, the ...
(Date:8/21/2014)... The report "Industrial Flue Gas ... System (FGD, DeNOx, Particulate Control, Mercury Control) by ... & Others) - Global Trends & Forecasts to ... gas treatment systems & services market with analysis ... terms of value. The industrial flue gas treatment ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... “Home Audio Equipment (Product Types - Home Theatre in-a-box, ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 15.94 billion in 2012 and is expected ... a CAGR of 3.7% from 2013 to 2019. Europe ...
Breaking Medicine News(10 mins):Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3
... carcinoma but relatively few patients are cured. Combined neoadjuvant ... survival but there is concern about treatment morbidity and ... research team from China used a prospective study, based ... postoperative CRT to surgery alone in patients with resectable ...
... idiopathic skeletal hyperostosis (DISH) is a common but ... people. All papers related to DISH demonstrate a ... advancing age. Various local structural lesions such as ... cervical osteophytes may lead to mechanical esophageal dysphagia. ...
... beyond the liver, researchers say , FRIDAY, April 9 ... virus are at much higher risk of developing kidney ... than 67,000 patients enrolled in the Henry Ford Health ... with hepatitis C developed kidney cancer. That,s double the ...
... , FRIDAY, April 9 (HealthDay News) -- Nearly half ... school-aged children are due to overuse -- and many ... the message from the just-launched Stop Sports Injuries campaign, ... and elite athletes, including professional golf legend Jack Nicklaus; ...
... ... New York Clinical Information Exchange, based in Buffalo, NY, has selected the Anakam to ... ... 9, 2010 -- Anakam announced today that HEALTHeLINK the Western New York Clinical Information ...
... Singapore ... procedures. With success rates topping 90 percent across a range of complex surgeries, the country ... ... National Eye Centre (SNEC) is the first and only specialist eye centre outside of ...
Cached Medicine News:Health News:Perioperative chemoradiotherapy in esophageal squamous cell carcinoma 2Health News:More Kids Falling Prey to Sports Overuse Injuries 2Health News:More Kids Falling Prey to Sports Overuse Injuries 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 2Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 4Health News:Singapore Performs Cutting-edge Eye Surgeries 2Health News:Singapore Performs Cutting-edge Eye Surgeries 3Health News:Singapore Performs Cutting-edge Eye Surgeries 4Health News:Singapore Performs Cutting-edge Eye Surgeries 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: